Cystic Fibrosis — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Correspondence: 'CFTR variants in bronchiectasis'.
Yang Yuanli — Pulmonology (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41696981/
- 2.
Comment on "Prevalence, type, and clinical implications of CFTR variants in bronchiectasis".
Priya Shanvi et al. — Pulmonology (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41684272/
- 3.
'The Hero's journey': Narratives on the transition to motherhood with cystic fibrosis.
Haines Alena J et al. — British journal of health psychology (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41804034/
- 4.
Gegen Qinlian decoction alleviates bacterial diarrhea via Lactobacillus amylovorus-modulated restoration of colonic water transport through the cAMP/CFTR/AQP3 pathway.
Luo Zhen-Ye et al. — Microbial pathogenesis (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41802655/
- 5.
L-ascorbic acid exerts anti-microbial and anti-virulence effects against multi-drug resistant Burkholderia cepacia complex.
Bhujbal Sourabh Rajendra et al. — Microbial pathogenesis (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41763415/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
Recruiting — Phase 2 — CSL Behring
https://clinicaltrials.gov/study/NCT07048262
- 2.
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
Recruiting — Phase 3 — Vertex Pharmaceuticals Incorporated
https://clinicaltrials.gov/study/NCT05422222
- 3.
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
Recruiting — Phase 1 — Respirion Pharmaceuticals Pty Ltd
https://clinicaltrials.gov/study/NCT06016088
- 4.
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
Recruiting — Phase 2 — The University of Queensland
https://clinicaltrials.gov/study/NCT04310930
- 5.
Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis
Recruiting — Phase 1 — Cystetic Medicines, Inc.
https://clinicaltrials.gov/study/NCT05802264
- 6.
Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta
Recruiting — Phase 2 — Sionna Therapeutics Inc.
https://clinicaltrials.gov/study/NCT07108153
- 7.
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
Recruiting — Phase 1 — Vertex Pharmaceuticals Incorporated
https://clinicaltrials.gov/study/NCT05668741
- 8.
Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.
Recruiting — Phase 1 — Sionna Therapeutics Inc.
https://clinicaltrials.gov/study/NCT07035990
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Cystic Fibrosis
Cystic fibrosis is a genetic condition that causes thick, sticky mucus to build up in the lungs and digestive system. It affects breathing and digestion. Treatments have advanced significantly, and many people with CF now live into adulthood and beyond.
Most Recent Research
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.